Question 1

How does Mitragyna inermis work against malaria?

Accepted Answer

Mitragyna inermis contains indole alkaloids, particularly mitraphylline and rhynchophylline, which are believed to exert anti-malarial activity through interference with Plasmodium parasite metabolism. These alkaloids may disrupt parasite membrane function or inhibit essential enzymatic pathways. Laboratory studies demonstrate in vitro activity against malaria-causing parasites, though the precise molecular mechanism remains under investigation. Evidence Level: C (preliminary research with limited human clinical data). Traditional use spans centuries in West African ethnomedicine.

Question 2

Does Mitragyna inermis interact with prescription medications?

Accepted Answer

Limited research exists on Mitragyna inermis drug interactions. As a relative of kratom (Mitragyna speciosa), it may theoretically interact with CNS depressants, opioids, and medications metabolized by hepatic cytochrome P450 enzymes. The alkaloid content suggests potential for pharmacokinetic interactions. Patients taking antimalarial drugs, sedatives, anticoagulants, or hepatotoxic medications should exercise caution. Evidence Level: C. Always consult a healthcare provider before combining with prescription medications.

Question 3

What is the recommended dosage of Mitragyna inermis bark?

Accepted Answer

Traditional preparations use 5-10 grams of dried bark as a decoction, taken twice daily for malaria and fever management. The bark is typically boiled in water for 15-20 minutes and consumed as tea. Standardized extracts lack established dosing guidelines. Evidence Level: C (based on traditional use and limited pharmacological data). Dosage should be individualized under guidance from a qualified herbalist or healthcare provider familiar with this botanical.

Question 4

Is Mitragyna inermis safe during pregnancy and breastfeeding?

Accepted Answer

Mitragyna inermis is considered unsafe during pregnancy and breastfeeding. The alkaloids present may cross the placenta and affect fetal development. Traditional contraindications explicitly warn against use in pregnant women. Related Mitragyna species have demonstrated potential uterine stimulant effects and reproductive toxicity in animal models. Evidence Level: C. Women who are pregnant, planning pregnancy, or breastfeeding should avoid this herb entirely due to insufficient safety data.

Question 5

What conditions is Mitragyna inermis traditionally used to treat?

Accepted Answer

Mitragyna inermis bark is traditionally used in West African medicine for malaria, fever, jaundice, edema, and liver disorders. Indigenous healers have employed this botanical for generations as a primary anti-malarial remedy. Additional applications include management of inflammatory conditions and general febrile illnesses. Evidence Level: C (preliminary pharmacological data supporting some traditional uses). This herb should not replace conventional antimalarial treatment without medical supervision.

Question 6

What are the side effects and contraindications of Mitragyna inermis?

Accepted Answer

Reported side effects include gastrointestinal upset, nausea, and abdominal discomfort. Due to its alkaloid content, higher doses may cause dizziness or sedation. Contraindications include pregnancy, breastfeeding, and liver disease due to potential hepatotoxicity. Patients with pre-existing hepatic conditions should avoid this herb. Evidence Level: C. Discontinue use if adverse reactions occur and seek medical attention for persistent or severe symptoms.

Mitragyna inermis

Sources et citations

Résumé

Contexte

Usages traditionnels

Composés actifs

Mécanisme d'action

Preuves cliniques

Sécurité et effets indésirables

Synthèse des preuves

Sources PubMed

Sources gouvernementales